JO3733B1 - استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة - Google Patents

استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة

Info

Publication number
JO3733B1
JO3733B1 JOP/2012/0065A JOP20120065A JO3733B1 JO 3733 B1 JO3733 B1 JO 3733B1 JO P20120065 A JOP20120065 A JO P20120065A JO 3733 B1 JO3733 B1 JO 3733B1
Authority
JO
Jordan
Prior art keywords
span
rtl
dir
compound
medicinal composition
Prior art date
Application number
JOP/2012/0065A
Other languages
English (en)
Inventor
Liu Ningshu
Schneider Claudia
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3733(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3733B1 publication Critical patent/JO3733B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بما يلي</span>: <span dir="RTL">استخدام مركب 2,3</span>-dihydroimidazo[1,2-c]quinazoline<span dir="RTL">، أو تركيبة دوائية تحتوي عليه، كعامل نشط مفرد، أو اتحاد من (أ) المركب المذكور أو تركيبة دوائية تحتوي على المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر، من أجل تحضير دواء لمعالجة أو الوقاية من السرطان؛ اتحاد من (أ) المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر؛ تركيبة دوائية تشتمل على المركب المذكور كعامل نشط مفرد من أجل معالجة سرطان الثدي؛ تركيبة دوائية تشتمل على اتحاد من (أ) المركب المذكور و(ب) عامل نشط إضافي واحد أو أكثر؛ استخدام علامة حيوية موجودة في تعديل إظهار</span> Bcl<span dir="RTL">، إظهار و/أو تنشيط عائلة</span> HER<span dir="RTL">، إرسال إشارة</span> PIK3CA <span dir="RTL">و/أو فقد</span> PTEN <span dir="RTL">للتنبؤ بالحساسية و/أو مقاومة مريض السرطان للمركب المذكور وتوفير اتحاد تآزري يعتمد على أساس منطقي كما تحدد هنا لزيادة الحساسية و/أو التغلب على المقاومة؛ و طريقة تحديد مستوى مكون من واحد أو أكثر من إظهار</span> Bcl<span dir="RTL">، إظهار و/أو تنشيط عائلة</span> HER<span dir="RTL">، إرسال إشارة</span> PIK3CA <span dir="RTL">و/أو فقد</span> PTEN.
JOP/2012/0065A 2011-04-05 2012-03-27 استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة JO3733B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161142 2011-04-05

Publications (1)

Publication Number Publication Date
JO3733B1 true JO3733B1 (ar) 2021-01-31

Family

ID=45894478

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0065A JO3733B1 (ar) 2011-04-05 2012-03-27 استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة

Country Status (29)

Country Link
US (1) US10202385B2 (ar)
EP (1) EP2694069A1 (ar)
JP (1) JP6013446B2 (ar)
KR (1) KR102006033B1 (ar)
CN (1) CN103608018B (ar)
AP (1) AP3751A (ar)
AR (1) AR088730A1 (ar)
AU (2) AU2012238887A1 (ar)
BR (1) BR112013025517A2 (ar)
CA (1) CA2832120C (ar)
CL (1) CL2013002869A1 (ar)
CU (1) CU24349B1 (ar)
DO (1) DOP2013000224A (ar)
EA (1) EA027670B1 (ar)
EC (1) ECSP13013007A (ar)
GT (1) GT201300235A (ar)
IL (1) IL228435A0 (ar)
JO (1) JO3733B1 (ar)
MA (1) MA35015B1 (ar)
MX (1) MX2013011582A (ar)
MY (1) MY169532A (ar)
PE (1) PE20140571A1 (ar)
PH (1) PH12013502066A1 (ar)
SG (1) SG193577A1 (ar)
TN (1) TN2013000402A1 (ar)
TW (1) TWI639599B (ar)
UA (1) UA114177C2 (ar)
UY (1) UY33984A (ar)
WO (1) WO2012136549A1 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2015160975A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
KR101665234B1 (ko) * 2015-02-10 2016-10-12 순천향대학교 산학협력단 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11253522B2 (en) * 2018-04-28 2022-02-22 The Regents Of The University Of California Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
US20210187134A1 (en) * 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1539891A (en) 1920-08-09 1925-06-02 Harry A Lewis Magnetic lifting device
US1450048A (en) 1921-09-24 1923-03-27 Mary S Patterson Nut lock
BE397809A (ar) 1932-08-25
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2002069896A2 (en) * 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
CA2491637A1 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
JP5190233B2 (ja) 2006-09-01 2013-04-24 パナソニック株式会社 無線通信装置
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US8128386B2 (en) 2008-06-26 2012-03-06 Hamilton Sundstrand Corporation Variable flow pumping system
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
JP5336306B2 (ja) 2008-10-20 2013-11-06 信越化学工業株式会社 レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料
CA2761736C (en) 2009-05-14 2017-09-26 Bayer Animal Health Gmbh Enhanced immune response in avian species
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
SI2654785T1 (sl) 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CN104661846B (zh) 2012-09-21 2017-03-22 丰田自动车株式会社 混合动力车辆用驱动装置

Also Published As

Publication number Publication date
UA114177C2 (uk) 2017-05-10
TN2013000402A1 (en) 2015-03-30
CA2832120C (en) 2020-10-27
AP3751A (en) 2016-07-31
EP2694069A1 (en) 2014-02-12
IL228435A0 (en) 2013-12-31
AU2012238887A1 (en) 2013-10-10
JP6013446B2 (ja) 2016-10-25
MX2013011582A (es) 2014-05-01
AU2017203474B2 (en) 2019-03-21
UY33984A (es) 2012-10-31
CN103608018A (zh) 2014-02-26
AR088730A1 (es) 2014-07-02
TWI639599B (zh) 2018-11-01
CN103608018B (zh) 2017-06-30
KR102006033B1 (ko) 2019-07-31
PH12013502066A1 (en) 2020-10-19
PE20140571A1 (es) 2014-05-19
NZ615502A (en) 2016-03-31
SG193577A1 (en) 2013-10-30
EA027670B1 (ru) 2017-08-31
AP2013007147A0 (en) 2013-09-30
WO2012136549A1 (en) 2012-10-11
AU2017203474A1 (en) 2017-06-08
KR20140025427A (ko) 2014-03-04
TW201245202A (en) 2012-11-16
EA201301106A1 (ru) 2014-03-31
JP2014514297A (ja) 2014-06-19
GT201300235A (es) 2014-08-27
MY169532A (en) 2019-04-22
CU24349B1 (es) 2018-06-05
CU20130134A7 (es) 2014-01-29
CL2013002869A1 (es) 2014-07-18
ECSP13013007A (es) 2013-12-31
US20140243295A1 (en) 2014-08-28
CA2832120A1 (en) 2012-10-11
BR112013025517A2 (pt) 2016-12-27
MA35015B1 (fr) 2014-04-03
US10202385B2 (en) 2019-02-12
DOP2013000224A (es) 2013-11-15

Similar Documents

Publication Publication Date Title
MY169532A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
UA109650C2 (xx) Біс-арилзв&#39;язані арилтриазолони та їх застосування
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA107827C2 (xx) Антитіло до cd40
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MX385217B (es) Antagonistas de actriib y dosificación y usos de los mismos.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
NZ625440A (en) Anti-cxcr1 compositions and methods
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
WO2013109279A3 (en) Stabilization of the anti-cd20 antibody rituximab
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EA201390925A1 (ru) Производные санглиферина и способы их получения